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Intraoperative autotransfusion (IAT) during aor-
tic surgery is widely practiced throughout North
America and has assumed the status of standard of
care.1-3 The objectives and potential benefits of IAT
are to (1) reduce net blood loss; (2) decrease the risk
of disease transmission; (3) prevent transfusion reac-
tion; (4) alleviate demands on blood bank invento-
ries; (5) provide an immediate source of blood dur-
ing unexpected bleeding; (6) provide a source of
blood to individuals who object to allogeneic blood
on religious or personal grounds; and (7) reduce
overall costs. Retrospective, nonrandomized studies
have attempted to define the benefit of IAT during
aortic surgery.4-10 Six studies compared patients
undergoing aortic surgery using IAT with historical
controls in which IAT was not used,4-9 and 1 study
used a nonrandomized, concurrent comparison
group.10 The data from these studies suggested that
routine IAT reduced allogeneic transfusion require-
ments by 50% to 80%, and all concluded that IAT
was safe, cost-effective, and highly beneficial. This
has led to the prevailing view that IAT is “…an essen-
tial part of all major aortic procedures where salvage
of blood shed into a body cavity is possible.”11
Despite these enthusiastic endorsements, recent
reports have questioned the benefits of IAT, particu-
larly when it is used in a routine fashion. Goodnough
et al12 retrospectively reviewed IAT in a large series of
patients undergoing abdominal aortic aneurysm
(AAA) repair at the Washington University School 
of Medicine and found that, despite large returns 
of IAT-processed blood, 88% of patients having
infrarenal AAA repair required allogeneic blood in
significant amounts (3.5 ± 2.0 units per patient).
They concluded that IAT would potentially be useful
only when the estimated blood loss (EBL) was more
than 1000 mL. In a thoughtful report, Huber et
al13,14 examined the benefits and costs of IAT in a
large series of patients undergoing aortic reconstruc-
tions at the University of Florida College of Medicine.
Using formal decision analytic techniques, they con-
cluded that routine IAT was not cost-effective.14
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In the only prospective, randomized study of
IAT in North America, Kelley-Patterson et al15 ran-
domized patients undergoing aortofemoral bypass
(AFB) to IAT and control groups, and they prospec-
tively assessed IAT in all patients undergoing AAA
repair. In patients undergoing AFB, the investigators
found no differences in total blood loss and allo-
geneic transfusion requirements. They also found
that blood loss among patients undergoing AAA
repair was not significantly different than that of
patients undergoing AFB. They concluded that rou-
tine IAT was unnecessary in patients undergoing
AFB and may not be beneficial even in patients
undergoing AAA repair.
Because of the controversy over routine IAT use,
we performed an open, randomized, prospective
trial of IAT in patients undergoing elective aortic
surgery. We hypothesized that there is no net bene-
fit of IAT in these patients.
METHODS
Patients undergoing elective AAA repair or AFB
for occlusive disease were eligible for entrance into the
study. Patients specifically excluded were those under-
going thoracoabdominal or suprarenal aneurysm
repair, concomitant renal or visceral artery recon-
struction, and reoperative aortic operations; those
with congenital or acquired bleeding disorders, crea-
tinine levels higher than 3 mg/dL, significant pre-
existing anemia (hemoglobin level [hgb] less than 10
g/dL), cirrhosis, and liver failure; those undergoing
an emergency operation; and those who refused to
join the study. Informed consent was obtained from
each patient before entry into the study, and the pro-
tocol was approved by the University of Texas
Southwestern Medical Center Institutional Review
Board and the Human Studies Committee of the
Dallas Department of Veterans Affairs (VA) Medical
Center. Randomization was carried out in blocks of
10 and was stratified for AAA repair or AFB. Patients
were randomized by means of a drawing of sealed
envelopes that contained prescriptions for either IAT
or control therapy. The study was unblinded.
Patients randomized to IAT received treatment
according to policies in force at the 3 teaching hos-
pitals of the University of Texas Southwestern
Medical Center. At all 3 hospitals, the Haemonetics
Cell Saver (Haemonetics Corp, Braintree, Mass) sys-
tem was used. At 2 hospitals (Zale Lipshy University
Hospital and the Dallas VA Medical Center), the Cell
Saver 3 Plus device was used and operated by a per-
fusion technician. At Parkland Memorial Hospital,
the Cell Saver 5 device was set up and run by trained
nurses. Both systems consist of polyvinyl aspiration
tubing with a separate channel for introducing small
amounts of heparinized saline solution (30,000 units
of heparin in 1000 mL of 0.9% normal saline solu-
tion) to anticoagulate aspirated blood, a plastic car-
diotomy reservoir with a microaggregate filter, a con-
tinuous flow, disposable washing bowl driven by a
centrifuge, and a transfusion setup that consists of a
plastic transfer pack passed to the anesthesiologist for
administration. Blood processed in this manner has a
hematocrit value (hct) of 55% to 60%; is free of par-
ticulate matter, plasma proteins, and platelets; con-
tains small amounts of heparin; and is referred to as
IAT packed red blood cells or IAT-PRBCs. The max-
imum allowable amount of IAT-PRBCs administered
to a single patient was 1500 mL.
All patients were given allogeneic packed red
blood cell transfusion (A-PRBCs) according to
guidelines,16 which included intraoperative transfu-
sion for hemodynamic instability and/or hgb less
than 10 g/dL (hct less than 30%), and postoperative
transfusion for hgb less than 8 g/dL (hct less than
25%), or hgb between 8 and 10 g/dL (hct, 25% to
30%) for those with compromised cardiopulmonary
status. Patients with hgb of 10 g/dL or more (hct,
Table I. Clinical characteristics and risk factors
Patients randomized Control patients 
to IAT (n = 50) (n = 50)
Age (years) 63 ± 11 65 ± 9
Men 41 (82%) 43 (86%)
AAA 25 (50%) 25 (50%)
Height (in) 69 ± 4 69 ± 6
Weight (kg) 77 ± 15 79 ± 15
AAA size (cm) 5.9 ± 1.9 6.0 ± 1.1
Intermittent claudication 27 (54%) 25 (50%)
Rest pain 20 (40%) 18 (36%)
Tissue loss 3 (6%) 6 (12%)
Cigarette smoking 33 (66%) 33 (66%)
Pack/d 1.5 ± 0.6 1.8 ± 1.7
Years 37 ± 12 36 ± 14
Diabetes mellitus 9 (18%) 11 (22%)
Hyperlipidemia 20 (40%) 19 (38%)
Hypertension 33 (66%) 35 (70%)
Coronary disease 23 (46%) 22 (44%)
COPD 7 (14%) 13 (26%)
Renal insufficiency 4 (8%) 11 (22%)*
(creatinine level, 
1.5 to 3.0 mg/dL)
ASA Classification
II 3 (6%) 6 (12%)
III 35 (70%) 35 (70%)
IV 12 (24%) 9 (18%)
IAT, Intraoperative autotransfusion; AAA, abdominal aortic
aneurysm; COPD, chronic obstructive pulmonary disease; ASA,
American Society of Anesthesiology.
*P = .05
30% or more) were not transfused. Patients random-
ized to IAT received IAT-PRBCs before A-PRBCs
were transfused. Those who had less than 400 mL of
blood salvaged did not receive IAT-PRBCs, because
these volumes were too small to process. These
patients received A-PRBCs if subsequent blood
transfusions were required.
The primary end points were the total amount of
allogeneic blood transfusion per patient during the
period of hospitalization and the proportion of
patients in whom allogeneic blood was not trans-
fused. Secondary end points included hematologic
parameters, fluid and colloid requirements, morbid-
ity, and mortality. In addition to the comparison
between all patients randomized to IAT and control
patients, a planned secondary analysis was to stratify
patients according to AAA repair and AFB. Blood
loss was monitored during operations according to
standard techniques that included sponge weights,
measurement of amounts collected in drainage can-
isters (minus total field irrigation with normal saline
solutions), and the estimates of nurses and anesthe-
siologists. Blood transfusion volumes were moni-
tored during operation and for the entire postoper-
ative period. In addition, the volumes of colloid,
electrolyte solutions, and blood component therapy
(fresh, frozen plasma and platelet concentrate) were
also noted.
Statistical analysis was done by Student t test for
continuous data, and all data presented in tables and
text are mean ± 1 SD. Proportional data were
assessed with the chi-square test (with and without
Yates correction) and Fisher exact test.
RESULTS
During a 16-month period (September 1996 to
December 1997), 100 patients were enrolled in this
study. This represents 58% of patients undergoing
elective aortic surgery at the hospitals affiliated with
the University of Texas Southwestern Medical Center
during this period. Reasons for exclusion included
patient refusal (27), supra or pararenal aneurysm
(22), concomitant renal or visceral reconstruction (9),
reoperative aortic surgery (5), creatinine levels more
than 3 mg/dL (4), thoracoabdominal aneurysm
repair (4), and preoperative anemia with hgb less than
10 g/dL (2). Fifty patients were randomized to each
group, with an equal distribution of patients having
aneurysm and occlusive disease. Patient demographics
and risk factors are shown in Table I. Most patients
were men, and the 2 groups were balanced for age,
body size (height and weight), presenting signs and
symptoms of occlusive disease, aneurysm size, athero-
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sclerotic risk factors, coronary artery disease, and
chronic obstructive lung disease. There were signifi-
cantly more patients with mild renal insufficiency
(creatinine level, 1.5 to 3.0 mg/dL) among control
patients. This population of patients was generally in
poor overall medical condition, with most being
American Society of Anesthesiology Class (ASA) III
and IV; only 6% to 12% were ASA II, and none were
ASA I. There were no differences between groups in
the ASA class distributions (Table I).
Operative details are shown in Table II. Again,
there was an excellent balance between groups in
types of aortic reconstruction (aortic tube, aortoiliac,
and aortobifemoral), types of prostheses, length of
operation, aortic crossclamp time, and total amounts
of heparin and protamine administered. At the con-
clusion of each operation, surgeons were asked to
record any episodes of unusual, “mechanical” bleed-
ing, defined as traumatic sources of blood loss that
were unanticipated during dissection, placement of
vascular clamps, suturing, or other manipulations
involving major veins (inferior vena cava, renal, iliac,
and lumbar), arteries (aorto-iliac, femoral, and lum-
bar), and anastomoses. These events were twice as
frequent (P < .01) among control patients.
Blood loss and replacement are displayed in
Table III. In addition to comparisons between all
patients randomized to IAT and control patients,
data from planned subgroup analysis of patients
undergoing AAA repair and AFB are also shown.
There were no differences between patients ran-
domized to IAT and control patients in the EBL, A-
PRBC transfusion (units administered intraopera-
tively, postoperatively, and total units), and propor-
tion of patients not receiving allogeneic transfusion
(34% of patients randomized to IAT and 28% of
control patients). Among patients randomized to
IAT, 74% were actually given processed IAT-PRBCs,
with the mean amount administered being 435 ±
301 mL (range, 200 to 1385 mL). The remainder of
the patients randomized to IAT had amounts of
blood salvaged in the Cell Saver that were too small
(less than 400 mL) to process. Most of those
patients were undergoing AFB. Ninety-six percent
of patients randomized to IAT undergoing AAA
repair received IAT-PRBCs, in comparison with 52%
of patients undergoing AFB (P < .001).
Patients randomized to IAT and control patients
undergoing AAA repair had significantly higher EBL
than those undergoing AFB (Table III). However,
this did not result in a greater overall need for A-
PRBC transfusion. In both groups, patients undergo-
ing AAA repair received slightly, but not significantly,
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more A-PRBC units than patients undergoing AFB.
In confining analysis to patients undergoing AAA
repair, those randomized to IAT required a total of
2.5 ± 2.5 A-PRBC units despite receiving 500 ± 322
mL of IAT-PRBCs, and control patients required 2.4
± 2.2 A-PRBC units. There were no significant dif-
ferences among patients randomized to IAT and con-
trol patients undergoing AAA repair in intraoperative,
postoperative, and total A-PRBC administration
(Table III). Likewise, among patients undergoing
AFB, there were no differences between IAT and con-
trol groups in intraoperative, postoperative, and total
A-PRBC transfusion. For all patients and subgroups,
about 60% of all A-PRBCs was given in the postoper-
ative period (Fig 1). This proportion of A-PRBCs
given postoperatively was similar for patients under-
going AFB and patients undergoing AAA repair.
Fluid and blood component therapies are shown
in Table IV. There were no significant differences
between patients randomized to IAT and control
patients in administration of types and amounts of
intraoperative and postoperative crystalloid, colloid,
albumin, fresh frozen plasma, and platelets.
Laboratory data are presented in Table V. Values
are tabulated for baseline (preoperative, or day –1),
immediately after operation (day 0), and the first 4
postoperative days. There were no significant differ-
ences between patients randomized to IAT and con-
trol patients in any of these laboratory parameters.
Notably, the expected drop in hct and hgb was sim-
ilar in each group, and at postoperative day 4 they
were almost identical (patients randomized to IAT,
hct = 31% ± 2%, hgb = 10.4 ± 0.7 g/dL; control
patients, hct = 31% ± 3%, hgb = 10.3 ± 1.1 g/dL).
In addition, the final hematologic values were simi-
lar at the time of discharge (patients randomized to
IAT, hct = 33% ± 4%, hgb = 11.2 ± 1.2 g/dL; con-
trol patients, hct = 32% ± 4%, hgb = 11 ± 1.3 g/dL).
There was no evidence of coagulopathy among
patients randomized to IAT (Table V).
Morbidity and mortality rates are presented in
Table VI. There were 2 deaths in the study (overall
mortality rate, 2%), and both were among control
patients. There were no significant differences in
cardiac, septic, gastrointestinal, or other complica-
tions. The total time spent in the intensive care unit
(patients randomized to IAT, 4.6 ± 1.4 days; con-
trols, 5.0 ± 1.6 days) and length of hospital stay
(patients randomized to IAT, 12.2 ± 4.7 days; con-
trols, 12.7 ± 5.3 days) were also similar.
Post hoc subgroup analyses were performed to
identify patients who might benefit from IAT. In the
first, all patients were separated into those with low
(less than 1000 mL) and high (1000 mL or more)
EBL (Table VII). Both patients randomized to IAT
and control patients with high EBL required signif-
icantly greater amounts of intraoperative, postoper-
ative, and total A-PRBC transfusions (P < .01).
Almost half of the patients randomized to IAT and
control patients with low EBL required no A-PRBC
transfusions. Patients randomized to IAT who had
1000 mL or more EBL received almost twice the
Table II. Operative details
Patients randomized Control patients 
to IAT (n = 50) (n = 50)
Reconstruction
Aortic tube 6 (12%) 7 (14%)
Aortoiliac 19 (38%) 20 (40%)
Aortobifemoral 25 (50%) 23 (46%)
Prosthesis
Knitted Dacron* 28 (56%) 34 (68%)
Woven Dacron 22 (44%) 16 (32%)
Anesthesia time (h) 5.4 ± 1.0 5.7 ± 1.6
Operation time (h) 3.8 ± 1.0 4.0 ± 1.4
Aortic crossclamp time (min) 75 ± 27 80 ± 37
Heparin (· 103 units) 12.6 ± 4.0 12.7 ± 3.8
Protamine (mg) 127 ± 49 129 ± 43
Unusual bleeding
Venous injury 0 3 (6%)
Lumbar arteries 3 (6%) 6 (12%)
Arterial injury 1 (2%) 3 (6%)
Anastomotic 6 (12%) 11 (22%)
Total 10 (20%) 23 (46%)†
IAT, Intraoperative autotransfusion.
*Collagen coated knitted Dacron.
†P < .01.
Fig 1. Time of allogeneic blood transfusion: intraopera-
tive, immediately after operation for 12 to 16 hours, and
postoperative days (POD) 1 to 4. Most (more than 60%)
allogeneic transfusions occurred after patients left the
operating room. There were no differences between
patients randomized to intraoperative autotransfusion and
control patients at any time.
amount of IAT-PRBCs (583 ± 339 mL) as patients
randomized to IAT with lower EBL (261 ± 85 mL;
P < .01) (Table VII). Despite receiving this amount
of IAT-PRBCs, high EBL patients randomized to
IAT showed no difference in intraoperative and
postoperative A-PRBC transfusions when compared
with control patients (Table VII). The total allo-
geneic transfusions among high EBL patients ran-
domized to IAT and control patients were 3.1 ± 2.0
and 3.9 ± 2.1 A-PRBC units, respectively.
In another subgroup analysis, only patients ran-
domized to IAT receiving 400 mL or more of IAT-
PRBCs were compared with control patients. This
analysis was carried out because 31 of the 50 patients
randomized to IAT received less than 400 mL of
IAT-PRBCs. Almost all these patients were under-
going AFB, and among the 19 patients receiving
400 mL or more of IAT-PRBCs, only 3 underwent
AFB. The 19 patients randomized to IAT receiving
greater amounts of IAT-PRBCs actually received sig-
nificantly more allogeneic transfusion, with this IAT
subgroup receiving 3.6 ± 2.3 A-PRBC units, in
comparison with 2.3 ± 2.1 units among control
patients (P = .03). In fact, for all patients random-
ized to IAT, there was a significant positive correla-
tion between the total amount of IAT-PRBCs
processed and administered and the total amount of
A-PRBCs given (correlation coefficient, r = 0.53; P
< .001; Fig 2).
DISCUSSION
Patients undergoing aortic surgery would appear
to be ideally suited to benefit from IAT. As we doc-
umented in a previous study, intraoperative blood
loss is greatest during the period of full hepariniza-
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tion,17 and anticoagulation therapy facilitates func-
tion of the IAT device. Blood shed during this peri-
od typically pools in the aneurysm sack, other
retroperitoneal spaces, and the pelvis, allowing easy
aspiration of nonclotting blood relatively free of air
and particulate matter. Despite the theoretical attrac-
tiveness of IAT in this setting, we could not show net
benefit from this practice. Allogeneic blood transfu-
sion was not reduced among all patients undergoing
aortic surgery nor in any subgroups that might be
more likely to benefit, such as those undergoing
operation for aneurysm, those having relatively high
blood loss, and those receiving larger volumes of
IAT-processed blood.
These results are at variance with many earlier
reports examining IAT,4-10 and differences are read-
ily apparent in the data presented in Table VIII.
EBL, IAT blood processed and administered,
amounts of allogeneic blood transfused, and the
proportion of patients not receiving allogeneic
blood vary widely. The heterogeneity of these stud-
ies reflects differences in study design (retrospec-
tive, observational, uncontrolled, and randomized,
controlled trials); patient mix (AAA, AFB, inclusion
of patients undergoing suprarenal and more com-
plex aortic procedures, elective and emergency
operations); individual surgeon and institutional
practices; and, possibly, different IAT devices. In
our study, we specifically excluded patients under-
going suprarenal aneurysm repair or simultaneous
renal/visceral reconstruction, and this may have
accounted for the lower EBL and salvage of blood
for IAT, in comparison with most other series. It is
possible that the inclusion of these patients would
have altered some of the outcomes and shown some
benefit of IAT in reducing allogeneic transfusion.
However, the recent large retrospective series of
Huber et al13 and Goodnough et al12 included
these patients and still could not demonstrate a def-
inite benefit of IAT.
It is rational to predict that the greater the
amount of blood loss during the operation itself, the
greater the potential usefulness of IAT. In a previous
study in which blood loss was closely monitored
during 3 phases of aortic operations (from skin inci-
sion to application of aortic crossclamp, during aor-
tic crossclamp, and after removal of crossclamp to
the end of the operation), blood loss was 2 to 5
times higher during the period of aortic crossclamp
while patients were heparinized.18 In the present
study, the amounts of blood salvaged during this
period were modest, and in a quarter of patients ran-
domized to IAT, salvage amounts were too small to
Fig 2. Relationship between total number of units of allo-
geneic blood administered and total amount of intraopera-
tive autotransfusion blood returned (r = 0.53, P < .001).
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process. This was especially true for patients under-
going AFB, 52% of whom received IAT-PRBCs, in
comparison with 96% of patients undergoing AAA
repair (P < .001). Despite this, restricting analysis to
patients undergoing AAA repair or to patients hav-
ing higher IAT salvage amounts failed to show a
decrease in allogeneic transfusion. In fact, the
greater the amount of return of IAT-PRBCs, the
greater the amount of allogeneic blood transfusion
(Fig 2). This simply indicates that greater blood loss
was occurring in these patients, and this relationship
is not surprising.
In addition to relatively small amounts of intra-
operative blood loss, ongoing postoperative blood
loss not amenable to salvage might account for the
inability of IAT to reduce allogeneic transfusion in
the present study. At least 60% of the total amount
of allogeneic blood given to control patients and
patients randomized to IAT was administered after
operation (Fig 1). Whether this need for additional
transfusion in the postoperative period is caused by
fluid shifts, time-related equilibration of hematolog-
ic parameters, or ongoing blood loss is unknown.
Because it is our practice that all patients leave the
operating room with an hct more than 30% (hgb
more than 10 g/dL), we suspect that ongoing blood
loss from retroperitoneal sources is significant. If so,
this might be a fruitful area of investigation to assess
effective topical hemostatic agents to reduce this
source of blood loss.
As in our previous study,17,18 we found no dif-
ference between patients undergoing AAA repair
and patients undergoing AFB in total allogeneic
transfusions, despite the EBL, blood salvage, and
return being greater in patients undergoing AAA.
This most likely is a reflection of the ease in
accounting for sudden blood loss at the time of
opening the aneurysm and the facility in salvaging
blood from the aneurysm sack. Patients undergo-
ing AFB have as much blood loss as patients under-
going AAA repair, but probably from different
anatomic sources and perhaps at different times
during the operation.
It is possible that lowering the hemoglobin
threshold for transfusion (transfusion “trigger”) may
have reduced overall allogeneic blood transfusion in
this study. Recent studies suggest that hgb less than
10 g/dL are tolerated without adverse events in
patients undergoing vascular surgery.19,20 Because
hgb and hct were virtually identical in control
patients and patients randomized to IAT, it is doubt-
ful that changing the threshold for transfusion
would have made any difference in the overall value
of IAT in reducing allogeneic blood transfusion.
Table III. Blood loss and replacement
Patients randomized to IAT Control patients
All (n = 50) AAA (n = 25) AFB (n = 25) All (n = 50) AAA (n = 25) AFB (n = 25)
EBL (mL) 981 ± 983 1418 ± 1192* 544 ± 389 1000 ± 787 1346 ± 920* 654 ± 417
A-PRBCs (U), 0.8 ± 1.2 0.9 ± 1.5 0.6 ± 1.0 1.0 ± 1.5 1.2 ± 1.5 0.8 ± 1.5
intraoperative
A-PRBCs (U), 1.3 ± 1.7 1.6 ± 1.9 1.1 ± 1.4 1.3 ± 1.4 1.2 ± 1.4 1.4 ± 1.4
postoperative
A-PRBCs (U), total 2.1 ± 2.1 2.5 ± 2.5 1.7 ± 1.6 2.3 ± 2.1 2.4 ± 2.2 2.1 ± 2.1
Number (proportion) 17 (34%) 8 (32%) 9 (36%) 14 (28%) 6 (24%) 8 (32%)
not given A-PRBCs
Number (proportion) 37 (74%) 24 (96%)* 13 (52%) — — —
given IAT-PRBCs
IAT-PRBCs (mL) 435 ± 301 500 ± 322 315 ± 220 — — —
IAT, Intraoperative autotransfusion; AAA, abdominal aortic aneurysm; AFB, aortofemoral bypass; EBL, estimated blood loss; A-PRBCs,
allogeneic packed red blood cells; IAT-PRBCs, intraoperative autotransfusion packed red blood cells.
*P < .001, AAA vs. AFB.
Table IV. Fluid and other component therapy
Patients randomized Control patients 
to IAT (n = 50) (n = 50)
Intraoperative
Crystalloid (L) 4.1 ± 2.2 4.8 ± 2.4
Colloid (L) 0.8 ± 0.8 0.5 ± 0.5
Albumin (g) 39 ± 41 34 ± 32
FFP (%) 10 (20%) 6 (12%)
Platelets (%) 1 (2%) 1 (2%)
Postoperative*
Cystalloid (L) 9.5 ± 3.7 9.8 ± 4.1
FFP (%) 4 (8%) 7 (14%)
Platelets (%) 3 (6%) 0 (0%)
IAT, Intraoperative autotransfusion; FFP, fresh frozen plasma.
*Postoperative duration of 4 days.
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Because this study was open (unblinded), it is
possible that there were sources of bias that may have
influenced outcomes. If so, it is likely to have favored
the use of IAT. Surgeons and anesthesiologists were
accustomed to using IAT during aortic surgery at our
institution, and some were initially reluctant to ran-
domize patients. An early concern was that anesthe-
siologists would be more likely to administer allo-
geneic blood to control patients simply because the
IAT device was absent. Also, “mechanical,” unex-
pected sources of blood loss were more frequent
among control patients. Although these events did
not lead to an overall higher EBL among control
patients, such events might have led to an increased
propensity to administer allogeneic blood.
Can the results of this study be extrapolated? We
believe they can. In the only other North American
randomized study of IAT, Kelley-Patterson et al15
demonstrated similar findings. They, like we, con-
cluded that routine IAT was not beneficial in
patients undergoing AFB. We have extended those
findings and conclude that routine IAT is also not
beneficial in patients undergoing infrarenal AAA
repair. Although we could not on subgroup analysis
demonstrate benefit in patients with higher blood
loss, it is possible that those undergoing suprarenal
AAA repair and more complex aortic surgery could
realize a reduction in allogeneic blood transfusion
requirements. These patients were excluded from
this study, and IAT may be beneficial under these
circumstances. However, based on recent analyses,
marginal reductions in allogeneic transfusion are
probably not cost-effective.12,14
Table V. Laboratory values
Patients randomized to IAT
Day –1 0* 1 2 3 4
Hct (%) 39 ± 5 32 ± 4 32 ± 4 31 ± 3 30 ± 2 31 ± 2
Hgb (g/dL) 13.0 ± 1.6 10.7 ± 1.4 10.9 ± 1.2 10.5 ± 1.0 10.3 ± 0.8 10.4 ± 0.7
WBC (· 103/m L) 8.6 ± 3.3 13.1 ± 4.8 11.6 ± 3.9 12.9 ± 4.3 11.7 ± 3.8 9.1 ± 2.8
Plts (· 103/m L) 246.5 ± 103.5 169.9 ± 73 167.8 ± 76.2 149.5 ± 65.4 150.5 ± 47.8 172.5 ± 62.9
PT (seconds) 12.0 ± 1.0 13.7 ± 1.3 13.2 ± 1.0 12.8 ± 1.0 12.2 ± 0.7 12.7 ± 0.9
aPTT (seconds) 27.2 ± 4.4 31.9 ± 15.5 31.0 ± 5.2 32.5 ± 7.3 31.0 ± 4.3 30.1 ± 8.2
Na (mEq/L) 139 ± 3 138 ± 3 137 ± 4 136 ± 3 137 ± 4 138 ± 4
K (mEq/L) 4.3 ± 0.4 4.1 ± 0.5 4.2 ± 0.3 4.0 ± 0.3 4.0 ± 0.4 3.8 ± 0.3
Creat (mg/dL) 1.0 ± 0.4 0.8 ± 0.3 0.9 ± 0.4 1.0 ± 0.7 0.9 ± 0.4 0.8 ± 0.4
Control patients
Hct (%) 40 ± 5 31 ± 4 32 ± 4 31 ± 3 31 ± 3 31 ± 3
Hgb (g/dL) 13.6 ± 1.6 10.6 ± 1.4 10.6 ± 1.9 10.5 ± 1.0 10.5 ± 1.0 10.3 ± 1.1
WBC (· 103/m L) 8.6 ± 2.5 13.0 ± 4.8 11.5 ± 3.7 12.7 ± 4.1 11.2 ± 3.2 9.6 ± 2.4
Plts (· 103/m L) 240 ± 76.6 165.2 ± 53.9 153.5 ± 50.3 135.7 ± 45.8 133.3 ± 45.0 158.1 ± 45.8
PT (seconds) 12.2 ± 1.3 13.9 ± 1.8 13.4 ± 1.4 13.5 ± 1.3 13.1 ± 1.3 13.7 ± 1.4
aPTT (seconds) 32.5 ± 20.2 32.0 ± 9.5 36.0 ± 8.4 34.9 ± 8.9 31.9 ± 4.7 32.9 ± 7.2
Na (mEq/L) 138 ± 3.5 137 ± 3.5 136 ± 3.5 134 ± 2.2 136.9 ± 4.0 138 ± 4.0
K (mEq/L) 4.4 ± 0.5 4.2 ± 0.5 4.3 ± 0.4 4.1 ± 0.3 4.0 ± 0.3 3.9 ± 0.3
Creat (mg/dL) 1.1 ± 0.4 0.9 ± 0.3 1.1 ± 0.4 1.2 ± 0.2 1.0 ± 0.4 1.0 ± 0.5
IAT, Intraoperative autotransfusion; Hct, hematocrit value; Hgb, hemoglobin level; WBC, white blood cell count; Plts, platelets; PT, pro-
thrombin time; aPTT, activated partial thromboplastin time; NA, sodium; K, potassium; creat, creatinine level.
*Day 0 = immediately postoperative.
Table VI. Morbidity and mortality
Patients randomized Control patients 
to IAT (n = 50) (n = 50)
Cardiac
MI 0 2 (4%)
Arrhythmia 5 (10%) 5 (10%)
CHF 1 (2%) 0
Septic
Pneumonia 0 3 (6%)
Urinary tract infection 2 (4%) 4 (8%)
Wound 3 (6%) 3 (6%)
Other
Stroke 0 1 (2%)
VTE 0 0
GI bleed 0 1 (2%)
Pancreatitis 1 (2%) 0
Lymph leak 2 (4%) 1 (2%)
Death 0 2 (4%)
IAT, Intraoperative autotransfusion; MI, myocardial infarction;
CHF, congestive heart failure; VTE, venous thromboembolism;
GI, gastrointestinal.
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Dr Kenneth Ouriel (Rochester, NY). Pat, that was a
very elegant and lucid presentation of some relatively
complex data, and I thank you for providing me with a
manuscript for review. 
You and your group from University of Texas
Southwestern Medical Center should be congratulated on
the execution of the study with a somewhat unique
design, a design all too seldom seen in our literature, a
prospective, randomized trial. Your group randomized
100 patients undergoing aortic repair to either homolo-
gous transfusion alone or autotransfusion. You found that
autotransfusion offered few advantages over homologous
transfusion. 
In fact, there were no statistical differences in the
amount of homologous blood transfused, irrespective of
whether blood shed at the time of operation was retrans-
fused or discarded. That’s the major problem that I have
with the data. The operative blood loss in the autotrans-
fusion and homologous groups was identical. The auto-
transfused patients received not only autologous blood,
but also a similar quantity of homologous blood. Why
were the postoperative hematocrit values identical when
the autotransfusion group received a greater amount of
total transfusion? 
Specifically, the autotransfused patients lost 1.0 L and
were retransfused 4.1 total units of blood, whereas the
homologous group lost a similar amount of blood, but
were retransfused only 2.3 units. Despite a difference of
almost 2 units of retransfusion between the 2 groups, the
postoperative hematocrit values were the same, and I won-
der if you can explain this apparent discrepancy? Were the
autotransfused patients experiencing hemolysis of the
retransfused blood? Were plasma-free hemoglobin levels
measured? Or, could the autotransfused patients have been
experiencing more postoperative intra-abdominal bleeding
from possibly an autotransfusion-induced coagulopathy? 
In a separate, but possibly related, issue, a design flaw
in the study might be the relatively small number of
patients enrolled. Is it possible that the statistical power of
the study was low enough that the probability of falsely
accepting the null hypothesis was great? Could true dif-
ferences between the groups have been missed on the basis
of a small sample size? 
In spite of these 2 issues, the work, I think, represents
the best comparison between 2 methods of blood replace-
ment to date. Although I might not agree with the con-
clusions, the performance of this prospective, randomized
trial should stand as a model for us all when we seek to
compare the outcome of 2 treatment modalities. 
I’d like to thank the Society for the privilege of dis-
cussing this stimulating study. 
Dr G. Patrick Clagett. Thank you, Ken, for your
insightful discussion. 
In response to your first question, I can’t totally explain
the apparent discrepancy that you point out. Theoretically,
the autotransfusion group received more blood, when you
count the autotransfusion blood plus the homologous
blood. However, there is substantial variance in all the data,
including blood loss and intraoperative and postoperative
transfusion amounts. The small incremental increase in
transfusion in the autotransfusion group could easily be
obscured in the “background noise” of this statistical vari-
ation. The data are as they stand, and we could detect no
differences between the groups. We did not measure plas-
ma-free hemoglobin levels, so I cannot comment on
whether the autotransfused blood underwent hemolysis.
According to the literature, this does not occur to a signif-
icant degree. If it did, this would further negate the bene-
fit of autotransfusion.
We did look at the question of coagulopathy occurring
in patients receiving autotransfused blood. This could occur
because of lingering heparin or dilution of blood elements
and coagulation factors. There was no significant increase in
the activated partial thromboplastin times and prothrombin
times or decrease in platelet counts among patients who
received autotransfusion blood, in comparison with control
patients. There was no evidence of coagulopathy even
among patients who received large amounts of autotransfu-
sion blood. So, we have no information that would suggest
that patients receiving autotransfusion blood had impaired
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hemostasis that would engender ongoing blood loss and the
need for more homologous transfusion. 
About the question of statistical power, there was
absolutely no trend to suggest that we had a type 2 statis-
tical error. It is always possible that if one extended the
trial to include 500 patients, or perhaps even 1000, that
there might be small differences showing benefit of auto-
transfusion. However, one would have to question the
cost/benefit of autotransfusion with such small differences
in relatively large numbers of patients.
We were, quite frankly, surprised by the data. I thought
this was going to be a positive study, showing a small but
significant reduction in homologous blood transfusion
among patients receiving autotransfusion. In fact, the orig-
inal protocol called for a decision analysis to determine
cost-effectiveness of autotransfusion in the event that the
study was positive. However, the study was so overwhelm-
ingly negative that this became a moot point.
Dr Thomas S. Huber (Gainesville, Fla). I’d like to
compliment the authors on a well-designed and executed
study and on the courage to present some data that con-
tradict the relative standard of care. 
We recently looked at the cost-effectiveness of the
device during elective infrarenal repair and found that the
cost-effectiveness breakpoint was in excess of 5 units of
Cell Saver salvage blood, even when all the long-term
complications of transfusion were modeled, and we con-
cluded that it wasn’t cost-effective in this setting. This
study further indicts the use of the device in this setting. I
would like to ask the authors what role they see for the
device in their clinical practice? 
Dr Clagett. We restrict the use of the autotransfusion
device to cases involving suprarenal and thoracoabdomi-
nal aneurysm repair. We no longer use the device for
standard infrarenal aortic surgery. 
Dr Daniel J. Reddy (Detroit, Mich). I also enjoyed
the study. Would you clarify, please, the method of intra-
operative autotransfusion that you used? I presume it was
washed, packed red cells, but if it was the whole blood
method, that would raise other issues to explain the lack
of benefit. Also, explain your use of the 10-gram transfu-
sion trigger. And also, do you not use autologous prede-
posit? Where does that fit into your program?
Dr Clagett. We use the cell saver device that is a
washed, packed cell system.
In response to your question regarding our “transfusion
trigger” of a hemoglobin level of 10 g/dL or a hematocrit
value of 30%, this was our standard of practice at the initia-
tion of the protocol. There are some older studies in the
anesthesia literature that show that the incidence of cardiac
arrhythmias and events increase dramatically in vascular
patients when perioperative hemoglobin and hematocrit
levels drop below this threshold. More recent studies have
documented that these threshold levels can probably be
safely lowered. However, even if we had lowered the “trans-
fusion trigger,” it wouldn’t have made any difference in the
outcomes, because it would have been the same for both
groups. The total amount of homologous blood transfusion
would be reduced in both groups, but there would not have
been significant differences between groups. 
Regarding the autologous predeposit, we use this
occasionally, but not routinely. It is logistically somewhat
difficult in our particular practice; however, I offer it as an
option for patients who desire this approach. There have
been good studies that have assessed this approach and
found it not to be cost-effective. 
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